1 Min Read
May 24 (Reuters) - Miragen Therapeutics Inc-
* Miragen Therapeutics receives EU orphan medicinal product designation for MRG-106 for the treatment of cutaneous t-cell lymphoma Source text for Eikon: Further company coverage:
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2017 Reuters. All Rights Reserved.